Novartis AG ADR (NVS-RMDR)

6,323.00
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    6,323.00 - 7,012.00
  • Type:Equity
  • Market:Russia
  • ISIN:US66987V1098

NVS-RMDR Overview

Prev. Close
7,011
Day's Range
6,323-7,012
Revenue
2.89T
Open
7,012
52 wk Range
5,814-7,035
EPS
-
Volume
0
Market Cap
11.8T
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
28
P/E Ratio
-
Beta
-
1-Year Change
-7.01%
Shares Outstanding
2,171,940,280
Next Earnings Date
-
What is your sentiment on Novartis ADR?
or
Vote to see community's results!

Novartis AG ADR News

  • Novartis Tops Q1 EPS by 2c
    • ByInvesting.com-

    Novartis (NYSE:NVS) reported Q1 EPS of $1.46, $0.02 better than the analyst estimate of $1.44. Revenue for the quarter came in at $12.53 billion versus the consensus estimate of...

  • Novartis ADR Earnings Beat, Revenue Misses In Q1
    • ByInvesting.com-

    Investing.com - Novartis ADR reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations. Novartis ADR announced earnings...

Novartis AG ADR Analysis

Novartis AG ADR Company Profile

Novartis AG ADR Company Profile

Employees
110000

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving Averages
Technical Indicators
Summary
  • https://seekingalpha.com/pr/18243773-sellas-life-sciences-reports-full-year-2020-financial-results-and-provides-business-update
    1
    • buy
      0
      • A
        0
        • just to know. I'm lost.this is the company that bought the medicines company?
          0
          • before investing in @novartis, read #teampia (twitter).
            0
            • sell 89 expecting 80 timeframe 5 days
              1
              • Long ENDOCYTE... I work in the field
                0
                • $NVS: Novartis AG Looking at All Options Including IPO for Alcon Unit.. This is HUGE catalyst for $NVS share holders!!!!!
                  0
                  • Buy this stock tomorrow as will be halted all day on Wednesday!
                    0
                    • I am willing to bet that FDA advisory committee WILL recommend their CTL019 drug!Post
                      0